About Semaglutide
Semaglutide is a synthetic GLP-1 receptor agonist used in metabolic and endocrine research. Supplied as a lyophilized powder for laboratory investigations of incretin receptor pharmacology, glucose-regulatory signaling, and downstream pathway activity in controlled experimental systems. Each batch is verified for identity and purity using HPLC and mass spectrometry. Supplied as: Lyophilized powder Purity: >95-99(HPLC verified) Storage: Store desiccated at ?20�C for long-term. Short-term room temperature exposure (around 1 month) during shipping/handling is generally acceptable if kept sealed, dry, and protected from heat/light. Designation: FOR RESEARCH USE ONLY. Not intended for human or animal consumption.
Latest Research
Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.
Recent research on Semaglutide: Unexplained hypercapnia with normal pulmonary evaluation in a patient receiving semaglutide: a diagnostic challenge.
Read Full Study on PubMedOral Semaglutide Sustains Long-Term CVD Risk Factor Reductions.
Recent research on Semaglutide: Oral Semaglutide Sustains Long-Term CVD Risk Factor Reductions.
Read Full Study on PubMedAdditional Studies
Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).
Recent research on Semaglutide: Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: a phase 3, randomized, active-controlled trial (SIZE-DM study).
Read on PubMedGlucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.
Recent research on Semaglutide: Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss.
Read on PubMedSemaglutide for obesity management: A narrative review of efficacy, safety, and future directions.
Recent research on Semaglutide: Semaglutide for obesity management: A narrative review of efficacy, safety, and future directions.
Read on PubMedTwo-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.
Recent research on Semaglutide: Two-Year Biomarker Trends and Kidney/Mortality Outcomes After Semaglutide Versus Phentermine-Topiramate and Naltrexone-Bupropion in People With Obesity and Without Diabetes.
Read on PubMedSemaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
Recent research on Semaglutide: Semaglutide Treatment in Young Adults Living With Type 2 Diabetes: A Post Hoc Analysis From the SUSTAIN and PIONEER Clinical Trials.
Read on PubMedUse of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
Recent research on Semaglutide: Use of Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease: Scandinavian Cohort Study.
Read on PubMedRelated Research
Purchase Semaglutide from Verified Peptides
High-purity research peptides with full analytical verification
- 99% Purity (HPLC Verified)
- Full Certificate of Analysis
- Same Day Dispatch
- Free UK Shipping Over £75
Research Disclaimer
The research articles and studies referenced on this page are for informational purposes only. All products are sold for research use only and are not intended for human or animal consumption. The information provided does not constitute medical advice, diagnosis, or treatment. Always consult with qualified healthcare professionals before making any decisions related to health or medical treatment.